At the outset of the pandemic, the life sciences industry made addressing the pandemic its top priority, devoting its resources, expertise, know-how, and intellectual assets to developing potential treatments, diagnostics and vaccines and committed to work in partnership with others at a record pace.<\/p>\n
The unprecedented nature and scale of the pandemic affirmed the importance of partnerships to scale up manufacturing, without compromising safety and quality. These collaborations were voluntary, varied and dynamic, requiring close working relationships amongst partners. How was this achieved?<\/p>\n
At the same time, the pandemic also highlighted bottlenecks. It heightened misperceptions about the complexity of these collaborations, including those relating to technology transfers and licensing models. Which lessons can be extracted from COVID-19 that can make these partnerships stronger, to be better prepared for future pandemics?<\/p>\n
On 7 June, IFPMA hosted a Geneva Pharma Forum, where partners involved in these collaborations shared their experience and discussed the elements and frameworks that foster them.<\/p>\n
Missed the event? Rewatch the recording below.<\/p>\n